Jointly provided by Postgraduate Institute for Medicine and Parkinson & Movement Disorder Alliance

Release date: October 23, 2021

Expiration date: October 23, 2023

Estimated time to complete activity: 4.5 hours

www.pimed.com

Target Audience

This activity is intended for clinicians engaged in the care of patients with Parkinson’s and other Movement Disorders.

Educational Objectives

After completing this activity, the participant should be better able to:

• Identify motor and non-motor treatments in movement and related disorders and their effects on patient quality of life.
• Utilize patient questionnaires and interview questions during the clinic visit to assess patient’s symptoms from movement and related disorders.
• Evaluate nonmotor symptoms in Parkinson’s and related disorders including cognitive issues and sialorrhea.
• Prescribe appropriate therapies to mitigate a multitude of motor and non-motor symptoms and improve patient outcomes.
• Manage the calculation of dose, titration, and effective programming of devices as appropriate.

Faculty

Fernando L. Pagán, MD
MedStar Georgetown University Hospital
Medical Director of Georgetown University Hospital
Director of Movement Disorders Program
Professor and Vice Chairman of Neurology

Yasar Torres-Yaghi, MD
MedStar Georgetown University Hospital
Director of the Parkinsonism and Dementia Clinic
Assistant Professor of Neurology

Elizabeth Epstein Mundel, MD
Medstar Georgetown University Hospital
Assistant Professor of Neurology

Dr. Laxman Bahroo, DO
Medstar Georgetown University Hospital
Vice Chair of Finance
Director, Residency Program
Director, Botulinum Toxin Clinic
Associate Professor of Neurology

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy.  PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Fernando L. Pagán, MD – Consulting Fees – Acorda, Amneal, Abbvie, Adamas, Kyowa Kirin, Merz, Lundbeck, Neurocrine, Sunovion, Supernus, Teva, US World Meds – Fees for Non-CE Services – Acorda, Amneal, Abbvie, Adamas, Kyowa Kirin, Merz, Neurocrine, Sunovion, Supernus, Teva, US World Meds – Contracted Research – Sun Pharma, US World Meds, Kyowa Kirin – Ownership Interest – Keiferx LLC – Other – Co-Founder and Board Member Keiferx LLC

Yasar Torres-Yaghi, MD – IP/Patent Holder – Mindsquare Technology – Consulting Fees – Abbvie, Acorda, Amneal, Acadia, Abbott, Sunovion, Teva, US World Meds, Biogen

Elizabeth Epstein Mundel, MD has nothing to disclose

Dr. Laxman Bahroo, DO, MS – Consulting Fees – Abbvie, Acadia, Acorda, Adamas, Amneal, Britannia, Ipsen Biopharma, Jazz Pharmaceuticals, Kyowa Kirin, Neurocrine, Revance, Supernus and Sunovion

The PIM planners and others have nothing to disclose. The PMD Alliance planners and others have nothing to disclose.

Joint Accreditation Statement 

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and PMD Alliance.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 4.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 4.5 contact hours.    

Computer System Requirements

A smartphone, tablet, or computer with access to the internet.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA.  The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development.  The information presented in this activity is not meant to serve as a guideline for patient management.  Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Method of Participation and Request for Credit

In order to obtain your CE certificate, please follow the directions provided at the conclusion of the course.  

If you have questions regarding the certification of this activity, please contact PIM via email at [email protected] or PMD Alliance at [email protected]